Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Broad Institute of MIT and Harvard, Cambridge, MA, United States of America.
PLoS One. 2022 Dec 1;17(12):e0271517. doi: 10.1371/journal.pone.0271517. eCollection 2022.
To examine the use of face mask intervention in mitigating the risk of spreading respiratory infections and whether the effect of face mask intervention differs in different exposure settings and age groups.
Systematic review and meta-analysis. We evaluated the risk of bias using the Cochrane Risk of Bias 2 tool (ROB2).
We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science were searched for randomized controlled trials investigating the effect of face masks on respiratory infections published between 1981 and February 9, 2022. We followed the PRISMA 2020 guidelines.
We included randomized controlled trials investigating the use of face mask intervention in mitigating the risk of spreading respiratory infections across different exposure settings.
We identified 2,400 articles for screening. 18 articles passed the inclusion criteria for both evidence synthesis and meta-analysis. There were N = 189,145 individuals in the face mask intervention arm and N = 173,536 in the control arm, and the follow-up times ranged from 4 days to 19 months. Our results showed between-study heterogeneity (p < 0.0001). While there was no statistically significant association over all studies when the covariate unadjusted intervention effect estimates were used (RR = 0.977 [0.858-1.113], p = 0.728), our subgroup analyses revealed that a face mask intervention reduced respiratory infections in the adult subgroup (RR = 0.8795 [0.7861-0.9839], p = 0.0249) and in a community setting (RR = 0.890 [0.812-0.975], p = 0.0125). Furthermore, our leave-one-out analysis found that one study biased the results towards a null effect. Consequently, when using covariate adjusted odds ratio estimates to have a more precise effect estimates of the intervention effect to account for differences at the baseline, the results showed that a face mask intervention did reduce respiratory infections when the biasing study was excluded from the analysis (OR = 0.8892 [0.8061-0.9810], p = 0.0192).
Our findings support the use of face masks particularly in a community setting and for adults. We also observed substantial between-study heterogeneity and varying adherence to protocol. Notably, many studies were subject to contamination bias thus affecting the efficacy of the intervention, that is when also some controls used masks or when the intervention group did not comply with mask use leading to a downward biased effect of treatment receipt and efficacy.
PROSPERO registration number CRD42020205523.
研究口罩干预在降低呼吸道感染传播风险中的作用,以及口罩干预在不同暴露环境和年龄组中的效果是否存在差异。
系统评价和荟萃分析。我们使用 Cochrane 风险偏倚 2 工具(ROB2)评估偏倚风险。
我们检索了 PubMed、Embase、Cochrane 对照试验中心注册库和 Web of Science,以查找 1981 年至 2022 年 2 月 9 日期间发表的关于口罩对呼吸道感染影响的随机对照试验。我们遵循 PRISMA 2020 指南。
我们纳入了研究口罩干预在不同暴露环境下降低呼吸道感染传播风险的随机对照试验。
我们筛选出了 2400 篇文章。18 篇文章同时通过了证据综合和荟萃分析的纳入标准。口罩干预组有 N = 189145 人,对照组有 N = 173536 人,随访时间从 4 天到 19 个月不等。我们的结果显示研究之间存在异质性(p < 0.0001)。虽然在未调整干预效果估计值的所有研究中,没有统计学意义上的关联(RR = 0.977 [0.858-1.113],p = 0.728),但我们的亚组分析显示,口罩干预可降低成人亚组(RR = 0.8795 [0.7861-0.9839],p = 0.0249)和社区环境中的呼吸道感染(RR = 0.890 [0.812-0.975],p = 0.0125)。此外,我们的逐个排除分析发现,一项研究使结果偏向于无效。因此,当使用调整协变量的比值比估计值来更精确地估计干预效果,以解释基线差异时,结果表明,当排除具有偏倚的研究时,口罩干预确实可以降低呼吸道感染的发生(OR = 0.8892 [0.8061-0.9810],p = 0.0192)。
我们的研究结果支持在社区环境和成人中使用口罩。我们还观察到研究之间存在很大的异质性和对方案的遵守程度存在差异。值得注意的是,许多研究受到污染偏倚的影响,从而影响了干预的效果,即当一些对照组也使用口罩时,或者当干预组不遵守口罩使用规定导致治疗效果的向下偏差时。
PROSPERO 注册号 CRD42020205523。